文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

A step closer to the use of [Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer.

作者信息

Jia Angela Y, Spratt Daniel E

机构信息

Department of Radiation Oncology, UH Seidman Cancer Center and Case Western Reserve University, Cleveland, OH 44106, USA.

Department of Radiation Oncology, UH Seidman Cancer Center and Case Western Reserve University, Cleveland, OH 44106, USA.

出版信息

Lancet Oncol. 2024 Oct;25(10):1246-1247. doi: 10.1016/S1470-2045(24)00506-0.

DOI:10.1016/S1470-2045(24)00506-0
PMID:39362242
Abstract
摘要

相似文献

[1]
A step closer to the use of [Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer.

Lancet Oncol. 2024-10

[2]
Exceptional 4-year response to Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer.

Eur J Nucl Med Mol Imaging. 2019-9

[3]
[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

Lancet. 2021-2-27

[4]
Preparation of Lu-PSMA-617 in Hospital Radiopharmacy: Convenient Formulation of a Clinical Dose Using a Single-Vial Freeze-Dried PSMA-617 Kit Developed In-House.

Biomed Res Int. 2021

[5]
Combining enzalutamide and [Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.

Lancet Oncol. 2024-5

[6]
Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot.

Lancet. 2024-9-28

[7]
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

N Engl J Med. 2021-9-16

[8]
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.

Eur Urol. 2018-11-22

[9]
A Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside?

Cancer Invest. 2020-9-14

[10]
Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617.

Clin Nucl Med. 2016-7

引用本文的文献

[1]
Advances in prostate-specific membrane antigen-targeted theranostics: from radionuclides to near-infrared fluorescence technology.

Front Immunol. 2025-1-10

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索